Clinical Research Department, Cardiovascular and Interventional Radiological Society of Europe, Vienna, Austria.
Next Research GmbH, Contract Research Organisation, Vienna, Austria.
J Med Imaging Radiat Oncol. 2023 Dec;67(8):903-914. doi: 10.1111/1754-9485.13529. Epub 2023 May 12.
Interventional oncology (IO) is an essential component of cancer care, which has gained substantial recognition in recent years. The aim of this review is to evaluate the level of evidence supporting IO and its inclusion in cancer treatment guidelines.
A literature search of the PubMed database was performed to identify publication numbers and types for IO treatments published between 2012 and 2022. Selected cancer treatment guidelines and recommendations were reviewed for their inclusion of IO treatments.
With 68%, the majority of studies on IO treatments are case reports while randomised controlled trials (RCTs) amount only to 7% of studies. Despite this, IO studies have generated sufficient data to support the inclusion of IO treatments in cancer treatment guidelines and recommendations. This was frequently based on large prospective patient cohorts that corresponded to 24% (20% non-randomised studies and 4% observational studies) of all analysed studies rather than RCTs.
The level of evidence underpinning IO, as well as inclusion of IO in treatment guidelines and recommendations have increased substantially in recent years, indicating the growing importance and acceptance of IO in cancer care. The difficulty in conducting RCTs in IO is mitigated by the observation that they are not necessary to achieve guideline-inclusion. Nevertheless, it is crucial to conduct well-designed research projects to further consolidate the position of IO in the field of oncology. This will ensure that IO continues to evolve and meet the needs of cancer patients worldwide.
介入肿瘤学（IO）是癌症治疗的重要组成部分，近年来得到了广泛认可。本综述旨在评估支持 IO 及其纳入癌症治疗指南的证据水平。
对 PubMed 数据库进行文献检索，以确定 2012 年至 2022 年间发表的 IO 治疗的出版物数量和类型。审查选定的癌症治疗指南和建议，以了解其对 IO 治疗的纳入情况。
IO 治疗的研究中，有 68%是病例报告，而随机对照试验（RCT）仅占研究的 7%。尽管如此，IO 研究已经产生了足够的数据，支持将 IO 治疗纳入癌症治疗指南和建议。这通常基于大型前瞻性患者队列，占所有分析研究的 24%（20%为非随机研究，4%为观察性研究），而不是 RCT。
近年来，IO 的证据水平以及 IO 在治疗指南和建议中的纳入情况有了显著提高，表明 IO 在癌症治疗中的重要性和接受程度不断增加。在 IO 中进行 RCT 的困难可以通过以下事实得到缓解：即使没有 RCT，也可以达到指南纳入的目的。然而，开展精心设计的研究项目至关重要，以进一步巩固 IO 在肿瘤学领域的地位。这将确保 IO 继续发展并满足全球癌症患者的需求。
